Zepbound injection sites: what the label and instructions say

Zepbound injection sites in the label

Zepbound (tirzepatide) is an FDA-approved, once-weekly injection given subcutaneously, meaning into the fatty layer under the skin. The prescribing information names three body areas and one rule: rotate the site every time (DailyMed, Aug 28, 2026). This page sets out what the label, the Medication Guide and the Instructions for Use (IFU) say. It does not teach technique. For that, use the IFU that comes with your presentation and ask your prescriber or pharmacist.

The label’s own wording is short: inject “in the abdomen, thigh, or another person should inject in the back of the upper arm,” then “Rotate injection sites with each dose” (DailyMed, Aug 28, 2026). The Medication Guide adds a route rule. Zepbound goes under the skin and should not be injected into a muscle or a vein (DailyMed, Aug 28, 2026).

Does the site change how much drug you absorb?

The label answers this directly. In its pharmacokinetics section, it states that “similar exposure was achieved” with doses in the abdomen, thigh or upper arm (DailyMed, Aug 28, 2026). Exposure means how much drug reaches the bloodstream over time.

So the label does not rank one site above another for effect. The single-dose pen IFU says your healthcare provider can help you choose the injection site that is best for you (DailyMed, Aug 28, 2026). The tirzepatide plotter models the weekly rise and fall in drug amount; site choice does not change its inputs.

Rotating sites and skin to avoid

Rotation appears in every Zepbound document. The Medication Guide says you may use the same area of your body but should choose a different injection site in that area, and should not use the same site for each injection (DailyMed, Aug 28, 2026). A KwikPen holds 4 weekly doses, so one pen spans four different spots.

The vial IFUs explain why rotation matters and list skin to skip (DailyMed, Aug 28, 2026):

• Rotating within the chosen area reduces the risk of lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps).
• Do not inject where the skin has pits, is thickened or has lumps.
• Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.
• Do not mix Zepbound with any other medicine, and do not use the same injection site used for other medicines.

Your healthcare provider should tell you whether to pinch the skin before a dose, per the vial IFU (DailyMed, Aug 28, 2026). That is a hands-on question for your prescriber or pharmacist.

What each presentation’s instructions say

Zepbound comes in four presentations, and each has its own IFU. The site wording differs slightly between them (DailyMed, Aug 28, 2026).

Other administration rules from section 2.4 of the label (DailyMed, Aug 28, 2026):

• Patients should be trained on the specific presentation they receive, and trained again if the presentation changes.
• The KwikPen is not recommended for self-administration by people who are visually impaired.
• People using vials should use a syringe suited to the dose, such as a 1 mL syringe that can measure 0.5 mL or 0.6 mL, and a new syringe and needle for each injection.
• Inspect the solution first. It should be clear and colorless to slightly yellow, and should not be used if particles or discoloration are seen.

Injection-site reactions in the trials

Reactions at the injection site were reported more often with Zepbound than with placebo (DailyMed, Aug 28, 2026).

The label also breaks rates out by antibody status. Injection-site reactions occurred in 11.3% of patients who developed anti-tirzepatide antibodies, versus 1% of those who did not (DailyMed, Aug 28, 2026). The Mounjaro label reports 3.2% versus 0.4% with placebo in its own pool, which is not directly comparable (DailyMed, Aug 27, 2026). For other effects, see the tirzepatide side effects guide.

Storage and in-use limits by presentation

Storage affects whether a dose is still usable on injection day. The limits differ by presentation, and the 21-day figure does not apply to KwikPens or multi-dose vials (DailyMed, Aug 28, 2026).

Rules that apply to every presentation (DailyMed, Aug 28, 2026):

• Do not freeze Zepbound, and do not use it if it has been frozen.
• Protect it from heat and light, and keep it in the original carton.
• Single-dose vials: use one per week and discard the unused portion.

The tirzepatide storage tool counts the 21-day and 30-day windows from a date you enter.

Mounjaro uses the same sites

Mounjaro contains the same drug, and its label names the same three sites with the same rotation rule (DailyMed, Aug 27, 2026). Its KwikPen IFU uses the same 2-inch belly-button wording (DailyMed, Aug 27, 2026). It adds one rule for people who also use insulin: give Mounjaro and insulin as separate injections and never mix them. The same body region is acceptable, but the injections should not be next to each other (DailyMed, Aug 27, 2026). The Mounjaro label also says its KwikPen is not recommended for self-administration by pediatric patients (DailyMed, Aug 27, 2026).

Where to get technique help

The label says patients should be trained on proper injection technique before starting, for the specific presentation prescribed (DailyMed, Aug 28, 2026). This page reports what the documents say about sites; it is not a substitute for that training. Read the Instructions for Use in your carton each time you start a new presentation, and ask your prescriber or pharmacist to walk you through it.

For dose steps and timing, see the Zepbound dosing schedule and the tirzepatide titration tool. The tirzepatide hub collects label facts for Zepbound and Mounjaro.